April 28, 2021

To
The Manager,  
**BSE Limited**  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**Scrip Code - 532523**

To
The Manager,  
**National Stock Exchange of India Limited**  
Corporate Communication Department  
Exchange Plaza, Bandra Kurla Complex  
Mumbai – 400 050

**Scrip Symbol - Biocon**

---

**Subject: Company Statement**

Dear Sir/Madam,

Please find attached a Company Statement titled “**Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.**”

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma  
Company Secretary and Compliance Officer
NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT

Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.

Bengaluru, India; April 28, 2021:

Biocon Ltd (BSE code: 532523, NSE: BIOCON) is pleased to announce that its Executive Chairperson Kiran Mazumdar-Shaw has been appointed to the Board of Trustees of Memorial Sloan Kettering Cancer Center (MSK), a world leader in cancer treatment and research, based in New York, U.S. She is among the 52 members on the board and will serve for a term of three years w.e.f. April 14, 2021.

Ms. Mazumdar-Shaw is the first woman of Indian nationality to be appointed for this prestigious role.

Memorial Sloan Kettering is ranked as one of the top two hospitals for cancer care in the U.S. for more than 30 years and among the nation’s top pediatric hospitals for cancer care, according to US News & World Report. Memorial Sloan Kettering maintains one of the world’s most dynamic programs of cancer research, with more than 120 research laboratories that are focused on better understanding every type of the disease.

For more information
seema.ahuja@biocon.com
+919972317792